These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 32040344)

  • 41. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LDH-A promotes malignant behavior via activation of epithelial-to-mesenchymal transition in lung adenocarcinoma.
    Hou XM; Yuan SQ; Zhao D; Liu XJ; Wu XA
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30509961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MicroRNA-147b promotes lung adenocarcinoma cell aggressiveness through negatively regulating microfibril-associated glycoprotein 4 (MFAP4) and affects prognosis of lung adenocarcinoma patients.
    Feng YY; Liu CH; Xue Y; Chen YY; Wang YL; Wu XZ
    Gene; 2020 Mar; 730():144316. PubMed ID: 31884109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
    Zhao Y; Gao Y; Xu X; Zhou J; Wang H
    BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PAR2 Promoter Hypomethylation Regulates PAR2 Gene Expression and Promotes Lung Adenocarcinoma Cell Progression.
    Wu K; Xu L; Cheng L
    Comput Math Methods Med; 2021; 2021():5542485. PubMed ID: 33968158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma.
    Wang L; Zhao H; Xu Y; Li J; Deng C; Deng Y; Bai J; Li X; Xiao Y; Zhang Y
    Int J Cancer; 2019 Apr; 144(7):1723-1734. PubMed ID: 30226269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of endothelin receptor type B (EDNRB) in lung adenocarcinoma.
    Wei F; Ge Y; Li W; Wang X; Chen B
    Thorac Cancer; 2020 Jul; 11(7):1885-1890. PubMed ID: 32394530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determining the Clinical Value and Critical Pathway of GTPBP4 in Lung Adenocarcinoma Using a Bioinformatics Strategy: A Study Based on Datasets from The Cancer Genome Atlas.
    Zhang Z; Wang J; Mao J; Li F; Chen W; Wang W
    Biomed Res Int; 2020; 2020():5171242. PubMed ID: 33134380
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High expression of keratin 6C is associated with poor prognosis and accelerates cancer proliferation and migration by modulating epithelial-mesenchymal transition in lung adenocarcinoma.
    Hu HB; Yang XP; Zhou PX; Yang XA; Yin B
    Genes Genomics; 2020 Feb; 42(2):179-188. PubMed ID: 31768767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. USP4 expression independently predicts favorable survival in lung adenocarcinoma.
    Zhong M; Jiang Q; Jin R
    IUBMB Life; 2018 Jul; 70(7):670-677. PubMed ID: 29667299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
    Zhang J; Sun G; Mei X
    Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aberrant expression of GSTM5 in lung adenocarcinoma is associated with DNA hypermethylation and poor prognosis.
    Hao X; Zhang J; Chen G; Cao W; Chen H; Chen S
    BMC Cancer; 2022 Jun; 22(1):685. PubMed ID: 35729618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype.
    Qin N; Ma Z; Wang C; Zhang E; Li Y; Huang M; Chen C; Zhang C; Fan J; Gu Y; Xu X; Yang L; Wei X; Yin R; Jiang Y; Dai J; Jin G; Xu L; Hu Z; Shen H; Ma H
    Theranostics; 2020; 10(24):11264-11277. PubMed ID: 33042282
    [No Abstract]   [Full Text] [Related]  

  • 55. Oncogenic role of miR‑183‑5p in lung adenocarcinoma: A comprehensive study of qPCR, in vitro experiments and bioinformatic analysis.
    He RQ; Gao L; Ma J; Li ZY; Hu XH; Chen G
    Oncol Rep; 2018 Jul; 40(1):83-100. PubMed ID: 29749535
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma.
    Shi YX; Zhu T; Zou T; Zhuo W; Chen YX; Huang MS; Zheng W; Wang CJ; Li X; Mao XY; Zhang W; Zhou HH; Yin JY; Liu ZQ
    Oncotarget; 2016 Dec; 7(51):85235-85243. PubMed ID: 27835911
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Mizuno K; Tanigawa K; Nohata N; Misono S; Okada R; Asai S; Moriya S; Suetsugu T; Inoue H; Seki N
    Cells; 2020 Sep; 9(9):. PubMed ID: 32932948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multi-platform analysis of methylation-regulated genes in human lung adenocarcinoma.
    Wang J; Yu XF; OUYang N; Luo QL; Zhao SY; Guan XF; Chen T; Li JX
    J Toxicol Environ Health A; 2019; 82(1):37-45. PubMed ID: 30626254
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
    Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
    Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.